DIABETIC NEPHROPATHY AN OBVIOUS COMPLICATION IN LONG TERM TYPE 1 DIABETES MELLITUS: A CASE STUDY

JAHDUL ISLAM MOHAMMAD*, SRIDEVI CHIGURUPATI**, AZLI SHAHRIL OTHMAN1, MUHAMMAD ZAHID IQBAL3

1Department of Pharmacology, Faculty of Medicine, Cyberjaya University College of Medical Sciences, CUCMS, Cyberjaya, Malaysia. 2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, AIMST University, Semeling, Bedong, Kedah, Malaysia. 3Department of Clinical Pharmacy, Faculty of Pharmacy, AIMST University, Semeling, Bedong, Kedah, Malaysia. Email: dr.jahid1980@gmail.com

ABSTRACT

Most overwhelming complications of Type 1 diabetes mellitus patients are responsible for complications related to the microvascular system most likely with kidney. In the kidney, hyperglycemia induced microangiopathy resulting not only thickening of the glomerular capillary basement membrane but also to the proliferation of the mesangial matrix and solidifying of the tubular basement membrane. Several biochemical and pathological, factors are concerned for the development of diabetic renal microangiopathy. These include the glomerular hyperperfusion and hyperfiltration, transformed morphology of podocytes accompanies these basement membrane modifications. Type IV collagen augmented synthesis following the hyperglycemia and increased expression of tissue matrix metalloproteinase. The aim of this case review is to highlight the recent advances in understanding the pathogenesis, diagnosis, the overview and the potential renoprotective therapeutic agents that would prevent the development or the progression of diabetic nephropathy.

Keywords: Type 1 diabetes mellitus, Albuminuria, Diabetic nephropathy.

INTRODUCTION

Diabetic nephropathy (DN) signifies one of the utmost common microvascular problems of Type 1 diabetes mellitus (T1DM) with an increasing frequency worldwide [1]. Which is well-defined as the presence of trace albuminuria followed by a diminished glomerular filtration rate (GFR) [2]. This signifies the inability of kidneys to prevent urinary protein leakage characterizes a significant prima sign of renal impairment in patients with T1DM [3]. One-third of T1DM patient’s progress to DN, on the other hand, this incidence is much lower with T1DM [4]. The most common complications of diabetes include macrovascular and microvascular events likewise-retinopathy induced blindness, heart attack, kidney failure, stroke, and leg amputation [5]. At present antidiabetic drugs are effective but implies very cost burden to the family. Moreover, a lot of cofactors such as patient devotion, education interrelated to diabetes, lifestyle modification, and associated comorbid diseases has an association with glycemic control [6]. The hallmark characteristics of DN is accompanied by numerous histological and functional anomalies, which includes loss of podocyte, thickening of glomerular basement membrane mesangial growth due to increased density of mesangial matrix and hypertrophy of mesangial cells (MCs) and hemodynamic changes in the initiation and progression of diabetic glomerulosclerosis, which resulting interruption and crumbling of the normal glomerular architecture which resulting microaneurysm formation [7]. American Diabetes Association characterized DN based on the extent of albuminuria and GFR. Renal hyperfunction and hypertrophy are categorized by the earliest stage (Stage 1) of DN. In the course of time and with the coexistence of risk factor such as uncontrolled hypertension, and persistent increase in urine albumin excretion (UAE) develops. This stage is called incipient nephropathy (Stage 3) characterized by GFR 30-59 ml/min/1.73 m², UAE>30 mg/day, >20 µg/min, or urine albumin to creatinine ratio (ACR) > 33 mg/g of creatinine. Stage 4 or overt nephropathy (renal failure) characterized as GFR shows a consistent decline (15-29 ml/min/1.73 m²) that becomes distinct with the continuous increase of UAE above 300 mg/day, 200 µg/min, or when urine ACR exceeds 300 mg/g. Stage 5 renal failure or end-stage renal disease signify constant increase of UAE above 300 mg/day and GFR below 15 ml/min/1.73 m² [8-10].

CASE REPORT

A 37-year-old woman is brought to the emergency department of a hospital with the complaints of unintentional weight loss, confused mental status, and dyspnea since last night. According to the patient, she is a known case of T1DM since her age is 8. It was treated with insulin lispro since diagnosis. Her family transfers to a new place of residence recently. She has 5 kg body weight without dieting and has been complaining of fatigue for 2 or 3 weeks. She appeared confused, forgetfulness, carelessness in dress and daily hygiene for the last 3 days. She also observed that her daughter is dyspeptic during walking around the house, washing, dressing, and even during eating since last night. 6 months before the admission, she noticed gradual swelling of whole body and puffiness of the face, which is more marked after getting up from sleep in the morning. She is hypertensive for past 5 years but has no history of allergy or bronchial asthma. She is under medication with insulin lispro and tablet losartan. Her parents are suffering from hypertension with dyslipidemia. However, they denied about diabetes or bronchial asthma. She was experiencing severe emotional trauma because of sudden loss of her 5 years old younger brother. There is no history of fever, abdominal pain, loin pain, itching, joint pain, skin rash, or hematuria.

On general examination, the patient is ill looking and pale, with puffiness of face and baggy eyelids, moderately anemic, pitting edema-present, she is hypertensive for past 5 years but no history of allergy or bronchial asthma. She is under medication with insulin lispro and tablet losartan. Her parents are suffering from hypertension with dyslipidemia. However, they denied about diabetes or bronchial asthma. She was experiencing severe emotional trauma because of sudden loss of her 5 years old younger brother. There is no history of fever, abdominal pain, loin pain, itching, joint pain, skin rash, or hematuria.

On general examination, the patient is ill looking and pale, with puffiness of face and baggy eyelids, moderately anemic, pitting edema-present, she is hypertensive for past 5 years but...
On laboratory investigation reveals hemoglobin: 9.3 g/dl (12-16), fasting blood glucose: >18 mmol/L, HbA1c: 12.2% (4.4-6.4), albumin: 2.4 mg/dL (4.1-5.1), globulin: 4.1 mg/dL (1.5-3.9), urea: 31 mg/dL (8-20), creatinine: 2.9 mg/dL (0.35-0.58), Na+: 138 mEq/L (135-150), K+: 6 mEq/L (3.5-5.0), Cl:100 mEq/L (98-106), HCO3: 13 mEq/L (24-30), amion gap: 32 (12±4), arterial blood gas reveals pH 7.25 with PO2 92 mmHg, P CO2 30 mmHg, urinary ketone bodies: ++++, and urinary proteins: ++. Renal biopsy investigations show gradual loss of podocyte foot processes and narrowing of the filtration slits, with the simultaneous events of decrease number of podocytes. Basement membrane proliferation is associated with the changes of the visceral glomerular epithelial cells (periodic acid-schiff stain) as shown in Fig. 1. Ovoid or spherical, often laminated nodules of matrix located in the fringe of the glomerulus known as intercapillary glomerulosclerosis as shown in Fig. 2.

DISCUSSION

The effect of hyperglycemia and sudden weight loss is usually mediated through hemodynamic and multiple metabolic pathways in long term Type 1 diabetic patient [11,12]. Glucose homeostasis is accomplished through the coordinated actions of multiple vital organs, but mostly through equilibrium between the access of glucose into the circulation from the liver, and the uptake of glucose by skeletal muscle, adipose tissues and brain by the various glucose transporters [13]. Insulin, the principal controller of glucose metabolism and storage in retort to an increase in plasma glucose [14]. T cell-mediated autoimmune disorder relating destruction of the insulin secreting B cells in the pancreatic islets and reasons T1DM. Hyperglycemia due to more than 80% of B cells destruction leads to glycosuria, dehydration, causing fatigue, polyuria, nocturia, thirst, and polydipsia [15]. Insulin is the chief regulator not only of glucose metabolism but also of fatty acid and amino acid metabolism. Unrestrained lipolysis and proteolysis due to a severe lack of insulin consequence in sudden severe weight loss [16]. When the formation of ketone bodies excedes the capacity for their metabolism in the liver, which is triggered by rapid lipolysis in the absence of insulin, leading to elevated circulating free fatty acid levels which are referred as diabetic ketoacidosis [17]. The free fatty acids are catabolized into fatty acyl-CoA inside the liver cells, which later on converted to ketone bodies within the mitochondria of liver cells. Metabolic acidosis is resulting from the accumulation of ketone bodies in the plasma, which is a well-known complication of T1DM [18].

As per previous some studies, T1DM can induce expression of intrarenal RAS genes [19-21]. Mechanical stress increases angiotensin II (A2) production and up-regulates AT IR in podocytes at the basement membrane [22]. Increased A2 exacerbates glomerular hypertension. A2 causes the express of the protein component of the slit diaphragm of podocyte is called nephrin. Notch1 is a transmembrane receptor that plays a part in cell differentiation and renal development. Notch1 couples A2 with nephrin results its receptor down regulation. Activation of Notch1 receptor leads to the release of the active Notch1 intracellular domain (ICN1). On Notch1 signaling both ICN1 and snail translocate to the nucleus and share in repression of nephrin expression and podocyte apoptosis [23,24]. Increased activity of polyol pathway by increased glucose absorption raises intracellular glucose availability with resulting increased fructose synthesis. Fructose metabolism leads to increased intracellular uric acid (UA) synthesis [25]. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase enzyme stimulate by UA and causing increased intracellular oxidative stress, endothelial injury, RAS activation, increased epithelial-mesenchymal transition mitochondrial injury and adenosine triphosphate depletion [26]. Human glomerular MCs express NADPH oxidase and activates protein kinase C, mitogen activated protein kinase, and nuclear factor-jB (NF-jB) which eventually results in overproduction of extracellular matrix proteins [27]. Excess fibroblasts infiltrate the interstitium with consequent progressive interstitial fibrosis [28]. Hyperglycemia triggers increased intracellular fibroblast growth factor 23 (FGF23) is a phosphatonin responsible for renal phosphate elimination. FGF23 inhibits 1-a hydroxylase gene with consequent decreased calciotriol synthesis. The previous study shown an inverse relationship between calcitriol and renin levels [29,30].

Dipeptidyl peptidase-4 (DPP-4) is a cell surface amino-peptidase enzyme is found in many cell types, including the endothelial cells in multiple organs including the kidney, which plays a significant part in glucoregulation by thought-provoking insulin release in a glucose-dependent manner [31]. Recent data, however, recommend that DPP-4 action is progressive in patients with T1DM related to healthy controls independently of islet cell autoimmune antibody status, C-peptide concentration, over all disease period or glycated hemoglobin (HbA1c) [32]. In normoglycemic status, microRNA-29 (miR29) controls membrane DPP-4 through suppression of its gene. Such effect is lost when miR29 levels decrease in hyperglycemic environment [33]. Elevated endothelin level is a constant feature of diabetic patients. Endothelin-1 (ET-1) is involved in the development...
of DN [34]. DN is allied with increased countenance of surface DPP-4, predominantly on endothelial and tubular epithelial cells. This increased expression and activity targets a broad range of peptides within its vicinity [35]. Activated DPP-4 interacts with integrin β1 and induces its phosphorylation. Activated DPP-4 phosphorylated integrin β1 complex triggers transforming growth factor-β (TGF-β) receptor dimerization and activation of vascular endothelial growth factor receptor Type 1 [36]. Hyperglycemia, free oxygen radicals, and proteinuria causes activation of NF-κB is within the diabetic kidney [37]. Activated NF-κB binds within the nucleus to the promoter regions of several genes that mediate the pathogenesis of DN like those encoding TGF-β1, chemokine ligand 2 also recognized as MCP-1 and intercellular adhesion molecule 1 [38]. As a consequence, the diabetic kidney would be the site of macrophage recruitment and excess collagen deposition resulting solidifying of tubular basement membranes and nodular diabetic glomerulosclerosis which facilitates microangiopathy [39].

CONCLUSION
Managing diabetic patients to control blood sugar and its consequences only by insulin or oral hypoglycemic agents is often very tedious. The use of RAS gene blockers offers favorable effect on glomerular hyperfiltration. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors offer a new addition to hyperfiltration control does not require dose adjustment with progressive renal disease. Control of hyperuricemia and renal leukocyte recruitment inhibition can be achieved by Nf2 antagonists. Control of hyperphosphatemia and improvement of metabolic acidosis is required once the patient proceeds to Stage 4 chronic kidney disease. Finally, it should be emphasized that the oral hypoglycemic agents, namely, Metformin, pioglitazone, and SGLT2 inhibitors can be used in T1DM patients when developing DN.

ACKNOWLEDGMENTS
The authors would like to thank Collogues form AIMST university, Cyberjaya university college of medical science, Department of Pharmacology and most thankful to Prof. Dr. Sharfuddin Ahmed, the honorable Deputy vice chancellor of Bangabandhu Sheikh Mujib Medical University.

REFERENCES
1. Wen CP, Chang CH, Tsai MK, Lee JH, Lu PJ, Tsai SP, et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int 2017;92(2):388-96.  
2. Allison SJ. Diabetic nephropathy: Glucose metabolic flux in DN. Nat Rev Nephrol 2017;13(7):384.  
3. Axelgaard E, Østergaard JA, Thiel S, Hansen TK. Diabetes is associated with increased autoreactivity of mannan-binding lectin. J Diabetes Res 2017;2017:6368780.  
4. Aoki Y, Tanimoto I, Miyauchi Y, Suzuki Y, Shiojiri T. A case of anti- gluceroluric basement membrane glomerulonephritis complicated by Type 1 diabetes mellitus, mimicking urinary tract infection. Am J Case Rep 2017;18:308-12.  
5. Begum SM, Halalatha S. Characterization, in silico and in vitro determination of antidiabetic and anti-inflammatory potential of ethanolic extract of sargassum wighti. Asian J Pharm Clin Res 2017;1489:431-43.  
6. Bragg F, Holmes MV, Iona A, Guo Y, Du H, Chen Y, et al. Association between diabetes and cause-specific mortality in rural and Urban areas of China. JAMA 2017;317(3):280-9.  
7. Dabelea D, Stafford JM, Mayer-Davis EJ, D’Agostino R Jr, Dolan L, Imperatore G, et al. Association of Type 1 diabetes vs Type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA 2017;317(8):825-35.  
8. Dugbartey GJ. Diabetic nephropathy: A potential savior with “rotten-egg” smell. Pharmocul Rep 2017;69(2):331-9.  
9. Hirakawa Y, Tanaka T, Nangaku M. Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease. J Diabetes Investig 2017;8(3):261-71.  
10. Homma K, Yoshizawa J, Shima Y, Ozawa H, Igarashi M, Matsuoka T, et al. A dipeptidyl peptidase-4 inhibitor, teneligliptin, decreases plasma triglyceride-rich lipoprotein remnants in diabetic patients with chronic kidney disease undergoing hemodialysis. Drugs R D 2017.  
11. Irannajad A, Ghajar A, Afarideh M, Khajeh E, Noshad S, Esteghamati S, et al. Association of peripheral nefastin-1 with early stage diabetic nephropathy. Pathophysiology 2017;24(1):17-22.  
12. Jin L, Wang T, Jiang S, Chen M, Zhang R, Hu C, et al. The association of a genetic variant in SCAF8-CNKSR3 with diabetic kidney disease and diabetic retinopathy in a Chinese population. J Diabetes Res 2017;2017:6542689.  
13. Kennummer S, Lorenz G, Wobst J, Kessler T, Wen M, Günther R, et al. Dietary nitrate load lowers blood pressure and renal stress index in patients with chronic kidney disease: A pilot study. Nitric Oxide 2017;64:7-15.  
14. Khidr EG, Ali SS, Elshafey MM, Fawzy OA. Association of irisin and FNDC5 r16835198 G>T gene polymorphism with Type 2 diabetes mellitus and diabetic nephropathy. An Egyptian pilot study. Gene 2017;626:26-31.  
15. Xing Y, Lai J, Liu X, Zhang N, Ming J, Liu H, et al. Netrin-1 restores cell injury and impaired angiogenesis in vascular endothelial cells upon high glucose by PI3K/AKT-eNOS. J Mol Endocrinol 2017;58:167-77.  
16. Xu Z, Zhao D, Liu Z, Liu W. Molecular mechanism of smurf2 in regulating the expression of SnoN in diabetic nephropathy. Mol Med Rep 2017;15(5):2560-6.  
17. Yao M, Gao F, Wang X, Shi Y, Liu S, Duan H. Nov4 is involved in high glucose-induced apoptosis in renal tubular epithelial cells via Notch pathway. Mol Med Rep 2017;15(6):4319-25.  
18. Zhang H, Nair V, Saha J, Atkins KB, Hodgin JB, Saunders TL, et al. Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice. Kidney Int 2017; pii: S0858-2533(17)03020-2.  
19. Zanchi C, Maccioni D, Trionfini P, Tomasoni S, Rottoli D, Locatelli M, et al. MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy. Diabetologia 2017;60(6):1114-25.  
20. Yuan CM, Nee R, Ceckowski KA, Knight KR, Abbott KC. Diabetic nephropathy as the cause of end-stage kidney disease reported on the MDU Health website. J Diabetes Invest 2017;8:196-204.  
21. Zha D, Wu X, Guo P. Adiponectin and its receptors in diabetic kidney disease. Molecular mechanisms and clinical potential. Endocrinology 2017.  
22. Yokoi H, Mukayama M. Analysis of pathological activities of CCN proteins in fibrotic diseases: Kidney fibrosis. Methods Mol Biol 2017;1489:431-43.  
23. Xu L, Niu M, Yu W, Xia W, Gong F, Wang O. Associations of...
between FGF21, osteonectin and bone turnover markers in Type 2 diabetic patients with albuminuria. J Diabetes Complications 2017;31(3):583-8.
34. Xue R, Gui D, Zheng L, Zhai R, Wang F, Wang N. Mechanistic insight and management of diabetic nephropathy: Recent progress and future perspective. J Diabetes Res 2017;2017:1839809.
35. Yang S, Han Y, Liu J, Song P, Xu X, Zhao L, et al. Mitochondria: A novel therapeutic target in diabetic nephropathy. Curr Med Chem 2017.
36. Vitova L, Tuma Z, Moravec J, Kvapec M, Matejovic M, Mares J, et al. Early urinary biomarkers of diabetic nephropathy in Type 1 diabetes mellitus show involvement of kallikrein-kinin system. BMC Nephrol 2017;18(1):112.
37. Wanner N, Bechtel-Walz W. Epigenetics of kidney disease. Cell Tissue Res 2017;369(1):75-92.
38. Wasik AA, Dumont V, Tienari J, Nyman TA, Fogarty CL, Forsblom C, et al. Septin 7 reduces nonmuscle myosin II A activity in the SNAP23 complex and hinders GLUT4 storage vesicle docking and fusion. Exp Cell Res 2017;350(2):336-48.
39. Wimalasena S, Kendrick-Jones J, Hawkins S, Talreja H. Renal artery embolisation for uncontrolled hypertension in ESRD. N Z Med J 2017;130(1448):73-6.